Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Summary: Potent incretin‐based therapy shows promise for the treatment of obesity along with reduced incidence of cardiovascular events in patients with preexisting cardiovascular disease and obesity. This study assessed the efficacy and safety of the incretin‐based obesity treatments, once‐weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg, in people with obesity without diabetes. Of the 744 records identified, seven randomized controlled trials (n = 5140) were included. Five studies (n = 3288) investigated semaglutide and two studies (n = 1852) investigated tirzepatide. The treatment effect, shown as placebo‐subtracted difference, on body weight was −15.0% (95% CI, −17.8 to −12.2) with −12.9% (95% CI, −14.7 to −11.1) for semaglutide and −19.2% (95% CI, −22.2 to −16.2) for tirzepatide. The treatment effect on waist circumference was −11.4 cm (95% CI, −13.7 to −9.2) with −9.7 cm (95% CI, −10.8 to −8.5) for semaglutide and −14.6 cm (95% CI, −15.8 to −13.4) for tirzepatide. The adverse events related to semaglutide and tirzepatide were primarily of mild‐to‐moderate severity and mostly gastrointestinal, which was more frequent during the dose‐titration period and leveled off during the treatment period. This emphasizes that once‐weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg induce large reductions in body weight and waist circumference and are generally well‐tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“12,13 16 Exercise interventions typically result in modest weight losses of about 0 to 4 kg but with reduced fat mass and preserved lean mass, improving body composition.”
BackgroundOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 7×
“Since weight loss with semaglutide seems to continue for at least a year, 42,43 studies of shorter duration could underestimate the treatment efficacy.”
BackgroundMethodInfluentialProspective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 6×
“The included studies were all phase 3 randomized controlled trials investigating either the effect of subcutaneous semaglutide (five studies 29,42,43,55,56 ) or tirzepatide (two studies 57,58 ).”
BackgroundInfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Research works printed but not linked: 22
- 10.1186/s12889‐021‐12449‐2 · DOI · Paper page
- 10.1093/humrep/deac096 · DOI
- 10.1038/s41366‐021‐00788‐4 · DOI · Paper page
- 10.1503/cmaj.191707 · DOI · Paper page
- 10.1093/tbm/ibab110 · DOI
- 10.1038/s41467‐022‐32307‐y · DOI · Paper page
- 10.1093/jn/nxz296 · DOI · Paper page
- 10.1007/s40264‐019‐00812‐7 · DOI
- 10.4314/ahs.v19i3.35 · DOI · Paper page
- 10.1016/S0140‐6736(18)31773‐2 · DOI · Paper page
- 10.1080/00325481.2022.2147326 · DOI · Paper page
- 10.1016/s0140‐6736(21)01324‐6 · DOI · Paper page
- 10.1002/oby.23612 · DOI
- 10.15605/jafes.037.02.14 · DOI
- 10.1038/s41591‐022‐02026‐4 · DOI · Paper page
- 10.1371/journal.pone.0285197 · DOI · Paper page
- 10.1002/9781119536604 · DOI · Paper page
- Veritas Health Innovation.Covidence systematic review software. Accessed November 22 2023.www.covidence.org
- Cochrane Training. Review Manager (RevMan). Accessed November 22 2023.https://training.cochrane.org/online‐learning/core‐software/revman
- 10.1001/jama.2021.3224 · DOI · Paper page
- 10.1038/oby.2012.70 · DOI
- 10.1056/nejmoa066254 · DOI · Paper page
Cited by
Jensen, S. B. K., Sørensen, V., Sandsdal, R. M., Lehmann, E. W., Lundgren, J. R., Juhl, C. R., Janus, C., Ternhamar, T., Stallknecht, B. M., Holst, J. J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.16775 · Cited by 155
Self-citationCengiz, A., Wu, C. C., & Lawley, S. D. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16229 · Cited by 20
Less frequent dosing of GLP‐1 receptor agonists as a viable weight maintenance strategy
Wu, C. C., Cengiz, A., & Lawley, S. D. (2025) · Obesity · doi:10.1002/oby.24302 · Cited by 9
“Meta-analyses of randomized controlled trials have indicated that semaglutide and tirzepatide facilitate an average placebo-adjusted body weight (BW) loss of 15.0% and 19.2% [ 1], respectively, compared with the 5% to 10% of older generation antiobesity medications (AOMs) [ 2].”
InfluentialBrain Activity Associated with Breakthrough Food Preoccupation in an Individual on Tirzepatide
Choi, W., Nho, Y.-H., Qiu, L., Chang, A., Campos, G., Seilheimer, R. L., Wilent, W. B., Bakalov, D., Firdous, N., Kerr, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04035-5 · Cited by 10
Jensen, S. B. K., Fiorenza, M., Juhl, C. R., Sandsdal, R. M., Jensen, E., Seier, S. S., Janus, C., Jørgensen, J. R., Blond, M. B., Holst, J. J., et al. (2026) · Sports Medicine · doi:10.1007/s40279-025-02386-0 · Cited by 9
“More effective pharmacotherapies are now available, reaching weight losses exceeding 20% [17].”
Self-citation
Metadata
- Authors
- Müllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2024-03-11
- Volume
- 25
- Issue
- 5
- Pages
- e13717-e13717
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W4392658789
- Cited by
- 46
- References
- 47
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Helsefonden (20‐B‐0389)
- Novo Nordisk Fonden (NNF22SA0079901, NNF16OC0019968, NNF15CC0018486, NNF23OC0084305)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. https://app.cochat.ai/papers/10.1111/obr.13717
- The paper
- Müllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S. (2024). Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity Reviews. https://doi.org/10.1111/obr.13717
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.